Contineum Therapeutics (NASDAQ:CTNM) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Contineum Therapeutics has received a "sell (D-)" rating from Weiss Ratings, while other analysts have issued a mix of ratings including "strong-buy" and "overweight."
• The company's stock is currently trading at $12.16 with a 52-week range of $3.35 to $20.24, and has a market capitalization of approximately $340.97 million.
• Contineum Therapeutics' latest earnings report showed a loss of ($0.62) EPS, missing analysts' expectations of ($0.56) by $0.06.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently commented on the company. Morgan Stanley raised their target price on Contineum Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Monday, August 18th. Leerink Partners began coverage on Contineum Therapeutics in a report on Thursday, September 25th. They set an "outperform" rating and a $20.00 target price for the company. William Blair began coverage on Contineum Therapeutics in a report on Friday, June 20th. They set an "outperform" rating for the company. Finally, Leerink Partnrs upgraded Contineum Therapeutics to a "strong-buy" rating in a research note on Thursday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Contineum Therapeutics currently has an average rating of "Buy" and a consensus target price of $22.20.

Contineum Therapeutics Stock Performance

Shares of NASDAQ CTNM traded up $0.77 during mid-day trading on Wednesday, reaching $12.16. 131,166 shares of the company's stock were exchanged, compared to its average volume of 203,597. The firm has a market capitalization of $340.97 million, a price-to-earnings ratio of -5.53 and a beta of 1.29. Contineum Therapeutics has a 52-week low of $3.35 and a 52-week high of $20.24. The company's 50-day moving average is $9.97 and its 200-day moving average is $6.44.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). As a group, equities analysts predict that Contineum Therapeutics will post -2.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Contineum Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in Contineum Therapeutics by 7.8% during the second quarter. Franklin Resources Inc. now owns 1,698,825 shares of the company's stock worth $6,744,000 after purchasing an additional 122,644 shares during the last quarter. Norges Bank acquired a new position in Contineum Therapeutics during the second quarter worth approximately $674,000. ADAR1 Capital Management LLC increased its position in Contineum Therapeutics by 105.2% during the first quarter. ADAR1 Capital Management LLC now owns 168,765 shares of the company's stock worth $1,178,000 after buying an additional 86,531 shares during the period. Monaco Asset Management SAM acquired a new position in Contineum Therapeutics during the second quarter worth approximately $298,000. Finally, RBF Capital LLC acquired a new position in Contineum Therapeutics during the second quarter worth approximately $159,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.